NCT02546661 - Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | Biotech Hunter

Enrollment

117

Participants

Timeline

Start Date

December 28, 2016

Primary Completion Date

March 18, 2020

Study Completion Date

January 9, 2026

Conditions

Muscle Invasive Bladder Cancer

Interventions

DRUG

AZD4547

AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.

DRUG

MEDI4736

DRUG

Olaparib

MEDI4736 (durvalumab) + Olaparib

DRUG

AZD1775

MEDI4736 (durvalumab) + AZD1775

DRUG

Vistusertib

MEDI4736 (durvalumab) + Vistusertib

DRUG

AZD9150

MEDI4736 (durvalumab) + AZD9150

DRUG

Selumetinib

MEDI4736 (durvalumab) + Selumetinib

Trial Locations (27)

10029

Research Site, New York

10032

Research Site, New York

10116

Research Site, New York

13273

Research Site, Marseille

14000

Research Site, Caen

28040

Research Site, Madrid

31100

Research Site, Toulouse

33075

Research Site, Bordeaux

33901

Research Site, Fort Myers

37203

Research Site, Nashville

44195

Research Site, Cleveland

44805

Research Site, Saint-Herblain

69373

Research Site, Lyon

90095

Research Site, Los Angeles

06510

Research Site, New Haven

T6G 1Z2

Research Site, Edmonton

V5Z 4E6

Research Site, Vancouver

M5G 2M9

Research Site, Toronto

H3T 1E2

Research Site, Montreal

08003

Research Site, Badalona

08035

Research Site, Barcelona

08041

Research Site, Barcelona

G12 0YN

Research Site, Glasgow

EC1M 6BQ

Research Site, London

W1G 6AD

Research Site, London

M20 4BX

Research Site, Manchester

SO16 6YD

Research Site, Southampton